Tech

Outrage grows as CDC reportedly poised to fund "unethical" vaccine trial

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 09/10/2026, 20:58:23 UTC.

Briefings

Health experts are outraged as the CDC reportedly plans to fund an unethical hepatitis B vaccine trial for newborns in Guinea-Bissau, despite the trial being suspended in January due to ethical violations. Staff of the CDC director's office instructed the agency's budget office in late September to set aside $1.6 million for the trial, which would divert funds from critical global health programs like Ebola response efforts. The trial remains halted, but the decision to allocate the money has sparked significant criticism. The Department of Health and Human Services did not respond to a request for comment from Ars Technica.

Key points

• The Centers for Disease Control and Prevention is reportedly planning to fund a hepatitis B vaccine trial for newborns in Guinea-Bissau, despite the trial being suspended in January due to ethical violations.
• CDC staff instructed the agency's budget office in late September to set aside $1.6 million for the trial, which would divert funds from critical global health programs like Ebola response efforts.

Context and limitations

The evidence indicates the trial remains halted but the decision to allocate the $1.6 million has sparked significant criticism. The Department of Health and Human Services did not respond to a request for comment from Ars Technica. Specific details on the trial's current status or the exact timeline of the budget decision beyond late September are not fully detailed in the provided source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 09/10/2026, 21:00:38 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifo7ajpe4x53sh75cguuup7uovnnrfaf3wikqvphlod6cd45rvkw4